http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-114848824-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-417 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-417 |
| filingDate | 2022-06-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2023-01-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2023-01-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-114848824-B |
| titleOfInvention | Application of nepicastat in preparation of medicine for treating sepsis |
| abstract | The present invention relates to the application of a dopamine-β-hydroxylase inhibitor in the preparation of medicines for treating sepsis. The present invention finds in the research that using the dopamine-β-hydroxylase inhibitor nepicastat to treat sepsis can effectively reduce the mortality rate of sepsis and alleviate the sepsis-induced heart, lung, liver, Intestinal and other multi-organ dysfunction. In addition, administration of dopamine-β-hydroxylase inhibitor nepicastat to neonatal rats with sepsis can effectively reduce the mortality of neonatal rats with sepsis. Nepicastat is expected to be well applied in the clinical treatment of sepsis and the multiple organ dysfunction caused by it. |
| priorityDate | 2022-06-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 143.